Search - tctmd.com

Displaying 1 - 20 of 127

Sort: Relevancy | Date

Presentation TCT 2025

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Under Pressure

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

NCD

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Welcome

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 90-Day Results from the US SUPPORT I Early Feasibility Study (EFS)

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Case 3: My Patient is on 6 Anti-Hypertensives - Are They Taking Them? and Is Renal Denervation Futile?

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

Presenter: David E. Kandzari

October 26, 2025

Presentation TCT 2024

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

Presenter: David Kandzari

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Presenter: David Kandzari

October 28, 2024

Presentation TCT 2023

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: David Kandzari

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Presentation TCT 2023

Securing Reimbursement: The Pathway to Financial Stability

Presenter: David Kandzari

October 24, 2023

Presentation TCT 2022

It’s Time We Had These Devices Approved and Reimbursed

Presenter: David E. Kandzari

September 18, 2022

Presentation TCT 2022

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Presenter: David Kandzari

September 17, 2022

Presentation TCT 2021

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Presenter: David E. Kandzari

November 04, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Todd Neale

November 04, 2021

Presentation TCT 2021

OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Presenter: David Kandzari

November 04, 2021

Advertisement

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

Under Pressure

NCD

Welcome

Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 90-Day Results from the US SUPPORT I Early Feasibility Study (EFS)

Case 3: My Patient is on 6 Anti-Hypertensives - Are They Taking Them? and Is Renal Denervation Futile?

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Securing Reimbursement: The Pathway to Financial Stability

It’s Time We Had These Devices Approved and Reimbursed

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content